RA Capital Management’s Ovid Therapeutics OVID Stock Holding History

RA Capital Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.2M	Sell	10,500,968 -213,032	-2%	-$550K	0.25%	55
2026 Q1	$23.8M	Hold	10,714,000	–	–	0.25%	53
2025 Q4	$17.5M	Buy	+10,714,000	New	+$16.5M	0.18%	51
2021 Q1	–	Sell	-285,000	Closed	-$658K	–	92
2020 Q4	$658K	Hold	285,000	–	–	0.01%	82
2020 Q3	$1.64M	Hold	285,000	–	–	0.03%	70
2020 Q2	$2.1M	Buy	+285,000	New	+$1.33M	0.04%	56

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

RA Capital Management's OVID Position: Q2 2026 in Review

RA Capital Management reduced its Ovid Therapeutics (OVID) stake by 2% in Q2 2026, selling an estimated $550K and leaving 10,500,968 shares worth $28.2M. The position accounts for 0.25% of the portfolio, ranked #55.

RA Capital Management first reported a position in OVID in Q2 2020 and has held it in 6 quarters since. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

RA Capital Management held 10,500,968 shares of Ovid Therapeutics worth $28.2M as of Q2 2026.
RA Capital Management sold 213,032 Ovid Therapeutics shares in Q2 2026, an estimated $550K.
Ovid Therapeutics made up 0.25% of RA Capital Management's portfolio in Q2 2026, its #55 holding.
RA Capital Management first reported a position in Ovid Therapeutics in Q2 2020 and has held it in 6 quarters since.
131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.